Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy

How I treat ADA deficiency

(2009) H. B. Gaspar et al.   BLOOD

The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy

(2009) Eugenio Montini et al.   JOURNAL OF CLINICAL INVESTIGATION

Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

(2009) Alessandro Aiuti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients

(2008) B. Cassani et al.   BLOOD

Toxicity of repeated intravenous injection of gene therapeutics for X-CGD in mice

(2008) YM Lee et al.   HUMAN & EXPERIMENTAL TOXICOLOGY

Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients

(2008) Steven J. Howe et al.   JOURNAL OF CLINICAL INVESTIGATION

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

(2008) Salima Hacein-Bey-Abina et al.   JOURNAL OF CLINICAL INVESTIGATION

Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16

(2008) U Modlich et al.   LEUKEMIA

Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors

(2008) Daniela Zychlinski et al.   MOLECULAR THERAPY